In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow

Imatinib mesylate (IM) is used to treat chronic myeloid leukemia (CML) because it selectively inhibits tyrosine kinase, which is a hallmark of CML oncogenesis. Recent studies have shown that IM inhibits the growth of several non-malignant hematopoietic and fibroblast cells from bone marrow (BM). The...

Descripción completa

Detalles Bibliográficos
Autores principales: Soares, P.B., Jeremias, T.S., Alvarez-Silva, M., Licínio, M.A., Santos-Silva, M.C., Vituri, C.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2012
Materias:
Biomedical Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854343/
https://www.ncbi.nlm.nih.gov/pubmed/23011404
http://dx.doi.org/10.1590/S0100-879X2012007500157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854343/
https://www.ncbi.nlm.nih.gov/pubmed/23011404
http://dx.doi.org/10.1590/S0100-879X2012007500157

Ejemplares similares